Kakkar A K
Barts and the London School of Medicine and Dentistry, Thrombosis Research Institute, London, UK.
Best Pract Res Clin Haematol. 2009 Mar;22(1):147-51. doi: 10.1016/j.beha.2009.01.004.
Venous thromboembolism is a common complication in patients with malignant disease. The development of symptomatic thromboembolism is associated with a poor prognosis for patients with cancer. Retrospective analysis of studies comparing unfractionated heparin with low-molecular-weight heparin (LMWH) for the initial treatment of deep vein thrombosis indicated improved survival for cancer patients receiving LMWH therapy. Prospective studies exposing cancer patients to LMWH therapy, in the absence of established thrombosis, suggest that survival may be prolonged in these patients after LMWH exposure. Ongoing studies, with careful attention to distribution of prognostic variables for cancer outcome, will help to answer the question regarding whether LMWH may indeed be used for this indication.
静脉血栓栓塞是恶性疾病患者常见的并发症。有症状的血栓栓塞的发生与癌症患者的不良预后相关。对比较普通肝素与低分子量肝素（LMWH）用于初始治疗深静脉血栓形成的研究进行回顾性分析表明，接受LMWH治疗的癌症患者生存率有所提高。在未发生已确诊血栓形成的情况下，让癌症患者接受LMWH治疗的前瞻性研究表明，这些患者在接受LMWH治疗后生存期可能会延长。正在进行的研究，仔细关注癌症预后的预后变量分布，将有助于回答关于LMWH是否确实可用于此适应症的问题。
